- Home
- TONX vs MOLN Comparison
TONX vs MOLN Comparison
Compare TONX & MOLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | TONX | MOLN |
|---|---|---|
| Founded | N/A | 2004 |
| Country | United States | Switzerland |
| Employees | 23 | N/A |
| Industry | Other Consumer Services | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 134.0M | 143.3M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | TONX | MOLN |
|---|---|---|
| Price | $3.18 | $4.02 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $8.38 |
| AVG Volume (30 Days) | ★ 506.6K | 9.4K |
| Earning Date | 05-12-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $374.07 |
| P/E Ratio | $0.26 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.75 | $3.41 |
| 52 Week High | $8.23 | $5.36 |
Technical Indicators
Market Signals| Indicator | TONX | MOLN |
|---|---|---|
| Relative Strength Index (RSI) | 51.21 | 52.43 |
| Support Level | $2.75 | $3.94 |
| Resistance Level | $3.59 | $4.49 |
| Average True Range (ATR) | 0.36 | 0.12 |
| MACD | 0.06 | 0.03 |
| Stochastic Oscillator | 69.17 | 66.12 |
Price Performance
Historical ComparisonAbout TONX TON Strategy Company
TON Strategy Co is a leader in interactive video-based sales applications, transforms how businesses attract and engage customers. The company's Software-as-a-Service platform, based on its proprietary interactive video technology, comprises a suite of easy-to-use, subscription-based sales enablement software products. The segments of the company are MARKET.live and Go Fund Yourself, and it derives maximum revenue from MARKET.live segment.
About MOLN Molecular Partners AG
Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company is currently focusing on oncology through their robust pipeline of clinical and preclinical programs, with particular attention to MP0712, the key Radio-DARPin candidate targeting DLL3 now in a Phase 1/2a trial in the United States.